Bortezomib对胃癌细胞增殖、细胞周期及核转录因子活性的影响

Effects of Bortezomib on proliferation, cell cycle and nuclear transcription factor activity of cells in gastric cancer cells

目的 观察Bortezomib对胃癌细胞周期、增殖、凋亡及核因子-κB（NF-κB）的影响。 方法采用噻唑蓝（MTT）法检测Bortezomib对细胞生长的抑制作用，流式细胞仪分析Bortezomib对细胞周期及凋亡的影响，Western blot检测Bortezomib对NF-κB、NF-κB抑制蛋白（IκB）和B细胞淋巴瘤/白血病-2（bcl-2）表达的影响。结果（1）Bortezomib对胃癌细胞的抑制作用具有剂量依赖性，随浓度的增加抑制作用增强（t＝7.418、5.131和6.438，P＝0.001、0.001和0.005）。（2）95D细胞出现明显的凋亡峰，与对照组G2/M期细胞所占的比例分别为（36.97±11.46）%和（19.17±5.37）%，两者比较差异有统计学意义（P＝0.031）；973细胞没有凋亡峰，与对照组比较，G2/M期细胞所占比例分别为（40.34±13.83）%和（13.10±4.72）%明显增加，两者比较差异有统计学意义（P＝0.037）；GLC82细胞既没有出现凋亡峰，也没有出现细胞周期明显改变，G2/M期细胞比例与对照组分别为（20.37±6.14）%和（12.15±2.63）%,两组比较差异无统计学意义（P＝0.173）。（3）胃癌细胞中均有NF-κB的基础性表达，且胞核中NF-κB的表达水平与胞质IκB的表达水平呈反比。（4）Bortezomib能明显下调抗凋亡蛋白bcl-2的水平，且这种抑制作用呈时间和剂量依赖趋势。不同浓度的Bortezomib作用后，细胞核中NF-κB的表达水平发生不同程度下降，差异有统计学意义（t＝6.373、4.273、3.841和4.414，P＝0.006、0.018、0.026和0.015）。结论Bortezomib能够抑制胃癌细胞增殖，并诱导凋亡发生，可能是通过NF-κB通路发挥作用。

Objective To investigate the effect of Bortezomib on cell cycle, proliferation, apoptosis and nuclear factor-κB （NF-κB） in cells.Methods Methyl thiazol tetrazolium （MTT） method was used to detect the inhibitory effect of Bortezomib on cell growth, analyze the effect of Bortezomib on cell cycle and apoptosis by flow cytometry. The effect of Western blotting on NF-κB, inhibitor of NF-κB （IκB） and Bortezomib to detect the expression of B cell lymphoma/leukemia-2 （bcl-2）.Results （1） The inhibitory effect of Bortezomib on gastric cancer cells was dose-dependent and inhibited with increasing concentration （t=7.418, 5.131 and 6.438, P=0.001, 0.001 and 0.005）. （2） 95D cell apoptosis peak appeared, and the control group accounted for the proportion of G2/M phase cells were （36.97±11.46）% and （19.17±5.37）%, respectively. The difference was statistically significant （P=0.031）; 973 cell apoptosis peak, compared with the control group, G2/M phase cells accounted for the proportion were （40.34±13.83）% and （13.10±4.72）%, respectively. The difference was statistically significant （P=0.037）; GLC82 cells neither apoptosis peak appeared, no obvious changes in cell cycle, the cell ratio of G2/M and the control group were （20.37±6.14）% and （12.15± 2.63）%, respectively. Two groups had no statistically significant difference （P=0.173）. （3） Basic expression of NF-κB was found in gastric cancer cells, and the expression level of NF-κB in nucleus was inversely proportional to the expression level of IκB. No significant effect on the expression level. （4） Bortezomib could significantly regulate the level of anti apoptotic protein bcl-2, and the inhibition was in a time and dose-dependent manner. After different concentration of Bortezomib, the expression level of NF-κB in nucleus decreased in different degrees, the difference was statistically significant （t=6.373, 4.273, 3.841 and 4.414, P=0.006, 0.018, 0.026 and 0.015）.Conclusion Bortezomib can inhibit the proliferation of gastric cancer cell line and induce apoptosis, which may play a role in NF-κB pathway.